Affiliation:
1. Department of Developmental Therapeutics, The University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston, Texas 77030
Abstract
The activity of azlocillin, a new semisynthetic penicillin, was determined against 582 clinical isolates of gram-negative bacilli and gram-positive cocci. Over 75% of the isolates of
Pseudomonas aeruginosa
were inhibited at a concentration of 12.5 μg or less per ml. Azlocillin is also active against indole-negative and -positive
Proteus
spp., inhibiting 98 and 71%, respectively, at a concentration of 12.5 μg or less per ml. Isolates of
Klebsiella
spp. and
Enterobacter
spp. showed less susceptibility than isolates of
Escherichia coli
and
Serratia
spp. Gram-positive cocci except penicillin G-resistant
Staphylococcus aureus
were susceptible to azlocillin. Azlocillin failed to inhibit the growth of gram-negative bacilli when large inocula were used. It was more active in alkaline pH, but the type of medium used had little effect on its activity. Azlocillin was more active than mezlocillin, ticarcillin, and carbenicillin and as active as BLP-1654 against isolates of
P. aeruginosa
. It was not as active as mezlocillin against the majority of the other gram-negative bacilli.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
61 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献